Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2023
First Quarter 2023 Financial Results and Highlights
- Net revenue of
$1,015.8 million , up 10.9% compared to$915.8 million in the first quarter of 2022 - Gross profit of
$229.0 million , or 22.5% of net revenue, up 14.0% compared to$200.9 million , or 21.9% of net revenue, in the first quarter of 2022 - Net income of
$39.2 million , or$0.22 basic earnings per share, up 29.5% compared to net income of$30.3 million , or$0.17 basics earnings per share, in the first quarter of 2022 - Adjusted EBITDA of
$93.8 million , up 20.6% compared to$77.8 million in the first quarter of 2022 - Cash flow from operations of
$89.8 million compared to$32.7 million in the first quarter of 2022 - Cash and cash equivalents balance was
$297.8 million at the end of the first quarter of 2023 - Completed stock repurchase of approximately
$75.0 million Launched Naven Health , the national infusion nursing platform founded in the acquisitions of Infinity Infusion Nursing and Specialty Pharmacy Nursing Network- Received the 2023 Gallup Exceptional Workplace Award
Updated Full Year 2023 Financial Guidance
For the full year 2023,
- Net Revenue of
$4.15 billion to$4.375 billion - Adjusted EBITDA of
$380 million to$395 million - Cash Flow from Operations of at least
$240 million
Additionally, the Company continues to anticipate an effective tax rate of 27% - 29% and net interest expense of approximately
The foregoing full year 2023 financial guidance excludes the impact of the Company's pending combination with Amedisys, Inc. ("Amedisys").
Conference Call
In a separate press release issued today,
About
Investor Contacts
|
|
Chief Financial Officer |
Westwicke |
T: (312) 940-2538 |
T: (413) 213-0500 |
Forward-Looking Statements - Safe Harbor
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long–lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of
Schedule 1 |
|||
CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)(UNAUDITED) |
|||
|
|
||
2023 |
2022 |
||
ASSETS |
|||
CURRENT ASSETS: |
|||
Cash and cash equivalents |
$ 297,776 |
$ 294,186 |
|
Accounts receivable, net |
395,209 |
377,542 |
|
Inventories |
249,643 |
224,281 |
|
Prepaid expenses and other current assets |
86,908 |
98,330 |
|
Total current assets |
1,029,536 |
994,339 |
|
NONCURRENT ASSETS: |
|||
Property and equipment, net |
105,571 |
108,321 |
|
Intangible assets, net |
21,677 |
22,371 |
|
Referral sources, net |
334,001 |
341,744 |
|
|
1,533,569 |
1,533,424 |
|
Other noncurrent assets |
106,048 |
112,737 |
|
Total noncurrent assets |
2,100,866 |
2,118,597 |
|
TOTAL ASSETS |
$ 3,130,402 |
$ 3,112,936 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
CURRENT LIABILITIES: |
|||
Accounts payable |
$ 448,890 |
$ 378,763 |
|
Other current liabilities |
169,676 |
186,588 |
|
Total current liabilities |
618,566 |
565,351 |
|
NONCURRENT LIABILITIES: |
|||
Long-term debt, net of discount, deferred financing costs and current portion |
1,057,787 |
1,058,204 |
|
Other noncurrent liabilities |
103,830 |
103,278 |
|
Total noncurrent liabilities |
1,161,617 |
1,161,482 |
|
Total liabilities |
1,780,183 |
1,726,833 |
|
STOCKHOLDERS' EQUITY |
1,350,219 |
1,386,103 |
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ 3,130,402 |
$ 3,112,936 |
Schedule 2 |
|||
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED) |
|||
Three Months Ended |
|||
2023 |
2022 |
||
NET REVENUE |
$ 1,015,848 |
$ 915,784 |
|
COST OF REVENUE |
786,843 |
714,848 |
|
GROSS PROFIT |
229,005 |
200,936 |
|
OPERATING COSTS AND EXPENSES: |
|||
Selling, general and administrative expenses |
147,866 |
133,969 |
|
Depreciation and amortization expense |
14,514 |
14,722 |
|
Total operating expenses |
162,380 |
148,691 |
|
OPERATING INCOME |
66,625 |
52,245 |
|
OTHER INCOME (EXPENSE): |
|||
Interest expense, net |
(13,834) |
(12,246) |
|
Other, net |
1,438 |
1,269 |
|
Total other expense |
(12,396) |
(10,977) |
|
INCOME BEFORE INCOME TAXES |
54,229 |
41,268 |
|
INCOME TAX EXPENSE |
15,021 |
10,993 |
|
NET INCOME |
$ 39,208 |
$ 30,275 |
|
Earnings per share, basic |
$ 0.22 |
$ 0.17 |
|
Earnings per share, diluted |
$ 0.21 |
$ 0.17 |
|
Weighted average common shares outstanding, basic |
181,262 |
179,961 |
|
Weighted average common shares outstanding, diluted |
182,735 |
181,681 |
Schedule 3 |
|||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)(UNAUDITED) |
|||
Three Months Ended |
|||
2023 |
2022 |
||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|||
Net income |
$ 39,208 |
$ 30,275 |
|
Adjustments to reconcile net income to net cash provided by operations: |
|||
Depreciation and amortization expense |
15,225 |
15,979 |
|
Other non-cash adjustments |
22,498 |
21,131 |
|
Changes in operating assets and liabilities: |
|||
Accounts receivable, net |
(17,812) |
(28,766) |
|
Inventories |
(25,362) |
(34,089) |
|
Accounts payable |
70,127 |
76,872 |
|
Other |
(14,132) |
(48,721) |
|
Net cash provided by operating activities |
89,752 |
32,681 |
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|||
Acquisition of property and equipment |
(5,760) |
(5,359) |
|
Net cash used in investing activities |
(5,760) |
(5,359) |
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|||
Purchase of company stock |
(75,000) |
— |
|
Other financing cash flows |
(5,402) |
(1,145) |
|
Net cash used in financing activities |
(80,402) |
(1,145) |
|
NET INCREASE IN CASH AND CASH EQUIVALENTS |
3,590 |
26,177 |
|
Cash and cash equivalents - beginning of the period |
294,186 |
119,423 |
|
CASH AND CASH EQUIVALENTS - END OF PERIOD |
$ 297,776 |
$ 145,600 |
Schedule 4 |
|||
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS)(UNAUDITED) |
|||
Three Months Ended |
|||
2023 |
2022 |
||
Net income |
$ 39,208 |
$ 30,275 |
|
Interest expense, net |
13,834 |
12,246 |
|
Income tax expense |
15,021 |
10,993 |
|
Depreciation and amortization expense |
15,225 |
15,979 |
|
EBITDA |
83,288 |
69,493 |
|
EBITDA adjustments |
|||
Stock-based incentive compensation |
5,988 |
4,178 |
|
Restructuring, acquisition, integration and other |
4,496 |
4,111 |
|
Adjusted EBITDA |
$ 93,772 |
$ 77,782 |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/option-care-health-announces-financial-results-for-the-first-quarter-ended-march-31-2023-301815206.html
SOURCE